Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) Shares Outstanding (Weighted Average) (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $7.5 million as the latest value for Q2 2020.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 3.29% to $7.5 million in Q2 2020 year-over-year; TTM through May 2020 was $7.5 million, a 3.29% decrease, with the full-year FY2019 number at $7.8 million, up 4.45% from a year prior.
  • Shares Outstanding (Weighted Average) was $7.5 million for Q2 2020 at Cryo Cell International, roughly flat from $7.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $7.8 million in Q3 2019 to a low of $7.2 million in Q2 2018.
  • A 3-year average of $7.6 million and a median of $7.5 million in 2020 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 7.66% in 2019, then decreased 3.34% in 2020.
  • Cryo Cell International's Shares Outstanding (Weighted Average) stood at $7.5 million in 2018, then grew by 4.45% to $7.8 million in 2019, then dropped by 3.2% to $7.5 million in 2020.
  • Per Business Quant, the three most recent readings for CCEL's Shares Outstanding (Weighted Average) are $7.5 million (Q2 2020), $7.5 million (Q1 2020), and $7.8 million (Q4 2019).